Compared with the full cohort, the remaining 2,066 POHS patients without AMD were younger (median 56 vs. 58 years) and less frequently had CNV codes (22% vs. 26%), any intravitreal injection (14% vs. 21%), and any anti-VEGF injection (9% vs. 14%). Here, VEGFA is linked to age-related macular degeneration.